Medical cannabis innovation
CanPharma is a GMP and GDP certified pharmaceutical company, holding licences for
manufacturing, import, and trade in pharmaceuticals, as well as the trade in controlled substances.
With a focus on importing rare genetics from the United States to licensed nurseries throughout the European Union, the company is dedicated to delivering the highest quality flowers to wholesale and retail partners in the EU and the UK.
Services extend to contract manufacturing, utilising cultivation facilities compliant with
Good Agricultural and Good Manufacturing Practices(GACP and GMP + across multiple
regions in the European Union, South America, and Africa.
Overview of CanPharma licenses
GMP Licenses
Good manufacturing practice (GMP) describes the minimum standard that a medicines manufacturer must meet in their production processes (according to art. 111 (5) of Directive 2001/83/EC)
Any manufacturer of medicines intended for the EU market, no matter where in the world it is located, must comply with GMP
Holding the GMP license is a mandatory prerequisite for the holding the manufacturing license (“Herstellungserlaubnis”)
Allows for import, bottling, repackaging, labelling and stability in house or through CMO for pharmaceutical products
Issued 23.12.2020
reissue after inspection, usually every three years, delayed by Covid 19
Approvals AmradV_20
Product related permission for the distribution of irradiated products (according to § 7 AMG and § 1 AMRadV)
It is prohibited to place on the market products in the manufacture of which ionising radiation has been used, unless this has been expressly authorised
According to Sec. 7 Subs. 2 AMG and Sec. 1 Subs. 2 regulation of medicinal products which are radioactive or treated with ionizing radiation (“AMRadV”)
Therefore, manufacturers require a further permit, if the products have been treated with ionized radiation
Issued 11.02.2020
valid for Bedrocan and Linneo products, have to be renewed after a period of 5years
GMP Licenses
Approvals AmradV_20
It is prohibited to place on the market products in the manufacture of which ionising radiation has been used, unless this has been expressly authorised